DUBLIN–(BUSINESS WIRE)–The “Sarcopenia
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.
Sarcopenia – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage
of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Sarcopenia (Musculoskeletal Disorders)
pipeline guide also reviews of key players involved in therapeutic
development for Sarcopenia and features dormant and discontinued
projects.
The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4,
1, 7, 2 and 2 respectively. Similarly, the Universities portfolio in
Preclinical and Discovery stages comprises 1 and 2 molecules,
respectively.
Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Sarcopenia (Musculoskeletal Disorders). -
The pipeline guide reviews pipeline therapeutics for Sarcopenia
(Musculoskeletal Disorders) by companies and universities/research
institutes based on information derived from company and
industry-specific sources. -
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
undisclosed stages. -
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
activities. -
The pipeline guide reviews key companies involved in Sarcopenia
(Musculoskeletal Disorders) therapeutics and enlists all their major
and minor projects. -
The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders)
therapeutics based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type. -
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects. -
The pipeline guide reviews latest news related to pipeline
therapeutics for Sarcopenia (Musculoskeletal Disorders)
Reasons to Buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies. -
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage. -
Find and recognize significant and varied types of therapeutics under
development for Sarcopenia (Musculoskeletal Disorders). - Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies. -
Plan mergers and acquisitions meritoriously by identifying key players
and it’s most promising pipeline therapeutics. -
Formulate corrective measures for pipeline projects by understanding
Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of
Indication therapeutics. -
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope. -
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Featured News & Press Releases
-
Dec 07, 2018: BIOPHYTIS announces one oral presentation and two poster
presentations at the 11th international conference on cachexia,
sarcopenia and muscle wasting -
Nov 27, 2018: BIOPHYTIS to host Key Opinion Leader Meeting on the
biology of Aging and its application in Neuromuscular Diseases -
Sep 04, 2018: Biophytis provides enrollment update in its phase 2b
SARA-OBS and SARA-INT studies of Sarconeos in sarcopenia -
May 24, 2018: BIOPHYTIS: Inclusion of the First Patient in Phase 2b
Study in Sarcopenia -
Mar 01, 2018: BIOPHYTIS updates on SARA clinical study of Sarconeos in
sarcopenia and presents four posters at the International Conference
on Frailty & Sarcopenia Research (ICFSR) in Miami -
Dec 08, 2017: Biophytis Presents 4 Posters on Sarconeos at 10th
International Conference on Cachexia, Sarcopenia, and Wasting
Disorders (SCWD) -
Dec 04, 2017: Biophytis has FAMHP Approval to conduct SARA-INT phase
2b Interventional Study of Sarconeos in Sarcopenia in Belgium -
Oct 30, 2017: BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b
Interventional Study of Sarconeos in Sarcopenia -
Sep 25, 2017: Biophytis filed IND application for approval by FDA of
SARA-INT Phase 2b study of Sarconeos in Sarcopenia -
May 11, 2017: BIOPHYTIS: First patient-in in the United States and
opening of 2 clinical centers for the SARA-OBS study on Sarcopenia -
May 03, 2017: BIOPHYTIS confirms that Sarconeos modulates the
Renin-Angiotensin System and activates muscular metabolism in the
SARA-PK clinical trial -
Mar 27, 2017: Biophytis opens the first clinical centers in Europe and
starts the recruitment of sarcopenic patients for SARA-OBS study -
Mar 21, 2017: BIOPHYTIS to present on BIO101 at the International
Conference on Frailty & Sarcopenia Research (ICFSR) in Barcelona -
Mar 01, 2017: BIOPHYTIS: Full results of SARA-PK study confirm
Sarconeos good pharmacokinetic profile in elderly patients -
Dec 16, 2016: Biophytis presents preliminary clinical data of SARA –
PK, and new preclinical data of Sarconeos for treating sarcopenia
Companies Mentioned
- Armgo Pharma Inc.
- Biophytis S.A.
- Faraday Pharmaceuticals Inc.
- Immusoft Corp.
- MYOS RENS Technology Inc.
- Neurotune AG
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- ST Pharm Co. Ltd.
- Teijin Pharma Ltd.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/qkmuvl
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Musculoskeletal
Disorders Drugs, Drugs
by Therapeutic Area